Sonia K Guterman, Age 8051 Winslow Rd, Belmont, MA 02478

6979538, Dec 27, 2005

Feb 14, 2001

09/781988

Robert Charles Ladner - Ijamsville MD, US
Sonia Kosow Guterman - Belmont MA, US
Bruce Lindsay Roberts - Milford MA, US
William Markland - Milford MA, US
Arthur Charles Ley - Newton MA, US
Rachel Baribault Kent - Boxborough MA, US

Dyax Corp. - Cambridge MA

C12Q001/68

435 6, 435 72, 435 71, 435 5, 435 4, 435DIG 5, 435DIG 3, 435DIG 2, 530350, 536 234

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

7078383, Jul 18, 2006

Jan 8, 2002

10/038722

Arthur C Ley - Newton MA, US
Sonia K Guterman - Belmont MA, US
William Markland - Milford MA, US
Rachel B Kent - Boxborough MA, US
Bruce L Roberts - Milford MA, US
Robert C Ladner - Ijamsville MD, US

Dyax Corp. - Cambridge MA

A61K 38/55
C07N 14/81
C12N 15/15

514 12, 530300, 530350, 435 692, 435 697, 514 2

Mutants of Kunitz domain 1 (ITI-D1) of human inter-α-trypsin inhibitor (ITI), are useful as inhibitors of human neutrophil elastase. Mutants characterized by one or more of the following substitutions (numbered to correspond to bovine pancreatic trypsin inhibitor, the archetypal Kunitz domain) are of particular interest: (a) Val15 or Ile15, (b) Ala16, (c) Phe18, (d) Pro19, (e) Arg1, (f) Pro2, and/or (g) Phe4.

7118879, Oct 10, 2006

Apr 22, 2002

10/126544

Robert Charles Ladner - Ijamsville MD, US
Sonia Kosow Guterman - Belmont MA, US
Bruce Lindsay Roberts - Milford MA, US
William Markland - Milford MA, US
Arthur Charles Ley - Newton MA, US
Rachel Baribault Kent - Boxborough MA, US

Dyax Corp. - Cambridge MA

C12Q 1/68

435 9, 435 6

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

7208293, Apr 24, 2007

Jun 29, 2001

09/893878

Robert Charles Ladner - Ijamsville MD, US
Sonia Kosow Guterman - Belmont MA, US
Bruce Lindsay Roberts - Milford MA, US
William Markland - Milford MA, US
Arthur Charles Ley - Newton MA, US
Rachel Baribault Kent - Boxborough MA, US

Dyax Corp. - Cambridge MA

C12Q 1/68

435 697, 435 691, 435 6, 435440, 435 5, 435 701, 530412

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

7413537, Aug 19, 2008

Jul 31, 2002

10/207797

Robert Charles Ladner - Ijamsville MD, US
Sonia Kosow Guterman - Belmont MA, US
Bruce Lindsay Roberts - Southborough MA, US
William Markland - Southborough MA, US
Arthur Charles Ley - Newton MA, US
Rachel Baribault Kent - Boxborough MA, US

Dyax Corp. - Cambridge MA

C40B 40/02

506 14, 530300, 530324, 530328, 530329, 530330, 435 5, 506 13

The invention relates, in part, to a library of chimeric proteins, each chimeric protein including a mini-protein between about eight and about forty amino acids long, wherein the mini-protein has a single disulfide bond formed by a pair of invariant cysteines and has only two cysteines. The chimeric protein also includes at least a portion of an outer surface protein of a genetic package, wherein the chimeric protein is displayed on the outer surface of the genetic package. The invention also includes, in part, a mixture of nucleic acids that encode a library of the invention. The invention also includes, in part, a process for identifying proteins with a desired binding activity against a target, the process including screening a library of chimeric proteins of the invention; and identifying the chimeric protein. The invention, in part, also includes chimeric proteins expressed by a library of the invention.

7893007, Feb 22, 2011

Oct 22, 2008

12/255793

Robert Charles Ladner - Ijamsville MD, US
Sonia Kosow Guterman - Belmont MA, US
Bruce Lindsay Roberts - Southborough MA, US
William Markland - Southborough MA, US
Arthur Charles Ley - Newton MA, US
Rachel Baribault Kent - Boxborough MA, US

Dyax Corp. - Cambridge MA

C40B 30/04

506 9, 506 7, 506 8, 506 13, 506 23, 435 5, 435 691, 435 692

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

2003021, Nov 27, 2003

Apr 22, 2002

10/126685

Robert Ladner - Ijamsville MD, US
Sonia Guterman - Belmont MA, US
Bruce Roberts - Milford MA, US
William Markland - Milford MA, US
Arthur Ley - Newton MA, US
Rachel Kent - Boxborough MA, US

C07K014/01
C12Q001/70
C07H021/04
C12P021/04
C12N001/21
C12N015/74

435/005000, 435/069700, 435/320100, 435/252300, 530/350000, 536/023720

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

2003021, Nov 27, 2003

Jun 29, 2001

09/896095

Robert Ladner - Ijamsville MD, US
Sonia Guterman - Belmont MA, US
Bruce Roberts - Milford MA, US
William Markland - Milford MA, US
Arthur Ley - Newton MA, US
Rachel Kent - Boxborough MA, US

C12N009/99

435/184000, 435/007100

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.